Last reviewed · How we verify
Arformoterol (Brovana)
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow.
Arformoterol is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow. Used for Maintenance treatment of chronic obstructive pulmonary disease (COPD), Maintenance treatment of asthma.
At a glance
| Generic name | Arformoterol (Brovana) |
|---|---|
| Sponsor | Trinity Health Of New England |
| Drug class | Long-acting beta-2 agonist (LABA) |
| Target | Beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | FDA-approved |
Mechanism of action
Arformoterol is the active (R,R)-enantiomer of formoterol, a long-acting beta-2 agonist (LABA). It binds to beta-2 adrenergic receptors on bronchial smooth muscle, activating adenylyl cyclase and increasing intracellular cAMP, which leads to smooth muscle relaxation and sustained bronchodilation. The drug provides 12-hour duration of action and is used in maintenance therapy for obstructive airway diseases.
Approved indications
- Maintenance treatment of chronic obstructive pulmonary disease (COPD)
- Maintenance treatment of asthma
Common side effects
- Tremor
- Headache
- Palpitations
- Muscle cramps
- Nervousness
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- A Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation (PHASE4)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Post-marketing Phase 4 Safety & Tolerability Study of Breztri aerosphereTM in Indian Patients With Chronic Obstructive Pulmonary Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Arformoterol (Brovana) CI brief — competitive landscape report
- Arformoterol (Brovana) updates RSS · CI watch RSS
- Trinity Health Of New England portfolio CI